(IBDX) iShares Trust - iShares - Ratings and Ratios
Corporate Bonds, Fixed-Income, Index Tracker
| Risk via 10d forecast | |
|---|---|
| Volatility | 3.44% |
| Value at Risk 5%th | 5.80% |
| Relative Tail Risk | 2.44% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.74 |
| Alpha | 3.04 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.498 |
| Beta | 0.092 |
| Beta Downside | 0.062 |
| Drawdowns 3y | |
|---|---|
| Max DD | 8.10% |
| Mean DD | 1.79% |
| Median DD | 1.55% |
Description: IBDX iShares Trust - iShares November 16, 2025
The iShares iBonds Dec 2032 Term Corporate ETF (NYSE ARCA: IBDX) seeks to track its benchmark by holding at least 80% of its assets in the index’s component securities and a minimum of 90% in fixed-income instruments that match the index’s composition, including non-U.S. corporate issuers when required for tracking fidelity.
Key metrics as of the latest reporting period: a weighted-average yield of roughly 4.3%, a modified duration near 8.5 years, and an average credit rating of “BBB-” (S&P), indicating exposure primarily to investment-grade corporates in Europe and Asia. The fund’s performance is sensitive to the Eurozone’s monetary-policy trajectory and corporate earnings trends in the industrial and technology sectors, which together drive credit spreads and default risk.
For a deeper, data-driven analysis of how IBDX’s risk-return profile fits your portfolio, you may find the ValueRay platform’s interactive dashboards useful for further investigation.
IBDX ETF Overview
| Market Cap in USD | 1,357m |
| Category | Target Maturity |
| TER | 0.10% |
| IPO / Inception | 2022-06-28 |
| Return 12m vs S&P 500 | -3.95% |
| Analyst Rating | - |
IBDX Dividends
| Metric | Value |
|---|---|
| Dividend Yield | 4.83% |
| Yield on Cost 5y | 5.77% |
| Yield CAGR 5y | 46.30% |
| Payout Consistency | 100.0% |
| Payout Ratio | - |
IBDX Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | 6.71% |
| CAGR/Max DD Calmar Ratio | 0.83 |
| CAGR/Mean DD Pain Ratio | 3.75 |
| Current Volume | 205.2k |
| Average Volume | 209.6k |
What is the price of IBDX shares?
Over the past week, the price has changed by +0.55%, over one month by -0.27%, over three months by +2.00% and over the past year by +7.23%.
Is IBDX a buy, sell or hold?
What are the forecasts/targets for the IBDX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 28.6 | 11.7% |
IBDX Fundamental Data Overview November 19, 2025
Beta = 1.23
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.36b USD (1.36b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 1.36b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 1.36b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 6.35% (E(1.36b)/V(1.36b) * Re(6.35%) + (debt-free company))
Discount Rate = 6.35% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for IBDX ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle